Coronavirus infection and systemic inflammatory reaction syndrome

Abstract

Aim: The purpose of this study was a clinical approbation of the Kometad drug (international non-proprietary name sodium colistimethate), an antibiotic from the polymyxin group in patients with severe course of confirmed сoronavirus infection in the intensive care unit of the Branch of the I. Zhekenova Municipal Clinical Infectious Diseases Hospital. Materials and Methods: The methodology is based on both theoretical and empirical methods of scientific cognition. During the study, the features of the Coronavirus infection and the inflammatory reaction syndrome were considered, which became quite a big problem during the pandemic. Results: The main indications for the tested drug and the consequences of its use for one age group were also determined. Conclusions: The conclusion was made about the positive dynamics of the patients’ health status, and recommendations were given for further research in this area. The practical significance of this study lies in the first clinical approbation of the Kometad drug, which can be used in medicine to reduce the severity of the systemic inflammatory reaction syndrome and improve the patient’s health as a result of the disease of Coronavirus infection, after further clinical trials of the drug with different age groups of patients.